Amarin highlights REDUCE-IT post hoc study linking icosapent ethyl to lower tissue factor levels, fewer CV events
AMRN•Guideline reference to REDUCE-IT RENAL
The 2026 ESC-ERA guideline cited REDUCE-IT RENAL evidence, supporting use of icosapent ethyl to reduce cardiovascular risk in appropriate patients.
REDUCE-IT post hoc analyses presented at ESC Congress 2026
Amarin highlighted new post hoc clinical analyses from REDUCE-IT presented at the ESC Congress 2026.
Data reinforced that icosapent ethyl lowered cardiovascular events in high-risk, statin-treated patients, including those with chronic kidney disease.
Mechanistic findings on EPA and anticoagulation-related pathways
Mechanistic results presented at the meeting linked EPA to reduced oxidation of atherogenic lipoproteins and to anticoagulation-related pathway effects.
